Changchun High-Tech's subsidiary, Gensci Pharmaceutical, has received approval from the U.S. FDA to commence clinical trials for its GenSci161 injection. This fully human bispecific antibody targets both IL-1α and IL-1β, aiming to improve treatment outcomes for moderate to severe hidradenitis suppurativa. The drug has previously been approved for clinical trials in China for conditions like endometriosis. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT N/A
RANK_REASON Drug clinical trial approval for a specific indication. [lever_c_demoted from research: ic=1 ai=0.1]